SOURCE: Kadmon Corporation

Kadmon Corporation

June 11, 2015 09:30 ET

Kadmon Corporation to Present at 17th Sino-American Pharmaceutical Professionals Association New England (SAPA-NE) Annual Conference

NEW YORK, NY--(Marketwired - Jun 11, 2015) - Kadmon Corporation, LLC today announced that Samuel D. Waksal, Ph.D., Founder, Chief of Innovation, Science and Strategy, and Chairman of the Board at Kadmon, will deliver the keynote address at the 17th Sino-American Pharmaceutical Professionals Association New England (SAPA-NE) Annual Conference, taking place on Saturday, June 13 in Cambridge, MA. Dr. Waksal will speak about the role of science and innovation in industry and academia.

SAPA is a U.S.-based non-profit organization for pharmaceutical professionals with Chinese heritage. Founded in 1993, SAPA has nearly 4,000 members in the United States and Asia. This year's SAPA-NE conference will focus on translational medicine to improve patient health outcomes. For more information, visit www.sapa-neweb.org.

About Kadmon Corporation
Kadmon Corporation, LLC is a vertically integrated biopharmaceutical company focused on developing innovative products for significant unmet medical needs. We have a diversified product pipeline in autoimmune and fibrotic diseases, oncology, monogenic diseases and metabolic disease. For more information, visit www.kadmon.com.

This press release contains forward-looking statements. These forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Kadmon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact Information

  • Contact Information
    Ellen Tremaine
    Investors
    646.490.2989
    Email Contact